Subcutaneous human menopausal gonadotropin administration for controlled ovarian hyperstimulation with intrauterine insemination cycles

American Journal of Obstetrics and Gynecology

Volumn 182, Issue 6, 2000, Pages 1421-1426

  Kaplan, Paul F ^a   Austin, Douglas J ^b   Freund, Richard ^b  

^a Women's Care Fertility Center   (United States)

^b NONE

Author keywords

Controlled ovarian hyperstimulation with intrauterine insemination; Gonadotropins; Subcutaneous human menopausal gonadotropin

Indexed keywords

HUMAN MENOPAUSAL GONADOTROPIN;

ADULT; BIOEQUIVALENCE; CONFERENCE PAPER; DRUG EFFECT; FEMALE; FERTILIZATION IN VITRO; HORMONE RELEASE; HUMAN; INJECTION SITE; INTRAUTERINE INSEMINATION; MAJOR CLINICAL STUDY; OVARY CYCLE; OVARY FOLLICLE MATURATION; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PRIORITY JOURNAL; PULSATILE FLOW;

EID: 0033917006     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2000.106131     Document Type: Conference Paper

References (14)

1. 1. Giudice E, Crisci C, Eshkol A, Papoian R. Composition of commercial gonadotropin preparations extracted from human postmenopausal urine: characterization of non-gonadotropin proteins. Hum Reprod 1994;9:2291-9.
2. 2. Archer DF, Zikria GA, Tyndall C, Mazer J. Ovarian follicular maturation in women. I. Intermittent versus daily administration of human menopausal gonadotropin. Fertil Steril 1986;46:1037-44.
3. 3. Messinis IE, Templeton AA, Baird DT. Comparison between clomiphene plus pulsatile human menopausal gonadotrophin and clomiphene plus pulsatile follicle stimulating hormone in induction of multiple follicular development in women. Hum Reprod 1986;1:223-6.
4. 4. Nakamura Y, Yoshimura Y, Tanabe K, Iizuka R. Induction of ovulation with pulsatile subcutaneous administration of human menopausal gonadotropin in anovulatory infertile women. Fertil Steril 1986;46:46-54.
5. 5. Nakamura Y, Yoshimura Y, Yamada H, Ubukata Y, Yoshida K, Tamaoka Y, et al. Clinical experience in the induction of ovulation and pregnancy with pulsatile subcutaneous administration of human menopausal gonadotropin: a low incidence of multiple pregnancy. Fertil Steril 1989;51:423-9.
6. 6. Nakamura Y, Yoshimura Y, Oda T, Shiokawa S, Yoshinaga A, Akiba M. Comparative study of hormonal dynamics in pregnant and nonpregnant cycles during pulsatile subcutaneous administration of human menopausal gonadotropin in anovulatory infertile women. Fertil Steril 1993;60:254-61.
7. 7. Engmann L, Shaker A, White E, Bekir JS, Jacobs HS, Tan SL. A prospective randomized study to assess the clinical efficacy of gonadotrophins administered subcutaneously and intramuscularly. Hum Reprod 1998;13:830-40.
8. 8. Engmann L, Shaker A, White E, Bekir JS, Jacobs HS, Tan SL. Local side effects of subcutaneous and intramuscular urinary gonadotropins for ovarian stimulation in in vitro fertilization: a prospective, randomized study. Fertil Steril 1998;69:836-40.
9. 9. Schmoutziguer AP, Van Kooy RJ, Koudstall J, Zonneveld P, Nan PM, Te Velde E. Subcutaneous administration of urinary gonadotropins: efficacy and safety in in-vitro fertilization. J Obstet Gynaecol 1996;16:409-13.
10. 10. Cohen J. Statistical power analysis for the behavioral sciences. Revised ed. New York: Academic Press; 1977.
11. 11. Duijkers IJ, Magnusson YM, Hollanders HM. Serum levels of follicle-stimulating hormone and luteinizing hormone after subcutaneous administration of human menopausal gonadotropin during pituitary suppression. Int J Fertil 1995;40:307-10.
12. 12. Huisman JA, Paulussen RJ, Geurts TB, Odink J, Rekers H. Assessment of bioequivalence after subcutaneous and intramuscular administration of urinary gonadotrophins. Hum Reprod 1997;12:34-8.
13. 13. Howles CM, Loumaye E, Giroud D, Luyet G. Multiple follicular development and ovarian steroidogenesis following subcutaneous administration of a highly purified urinary FSH preparation in pituitary desensitized women undergoing IVF: a multicentre European phase III study. Hum Reprod 1994;9:424-30.
14. 14. Wikland M, Borg J, Hamberg L, Svalender P. Simplification of IVF: minimal monitoring and the use of subcutaneous highly purified FSH administration for ovulation induction. Hum Reprod 1994;9:1430-6.